Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock (or pre-funded warrants) Closed: US$5M raised · US$0.985 a share · Warrants at US$0.86 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Commercial launch of LYMPHIR including milestone and regulatory payments, development of product candidates, and general corporate purposes | Apr 27, 2026 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants Closed: US$6M raised · US$1.51 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, including milestone and regulatory payments, development of product candidates, and general corporate purposes | Oct 21, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying short-term warrants Closed: US$6M raised · US$1.22 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, including milestone, regulatory and other payments, and general corporate purposes | Jun 12, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) Announced: about US$2M · US$1.15 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR and general corporate purposes | Apr 1, 2025 |
| Registered direct offering of shares of common stock and accompanying warrants Announced: about US$3M · US$4.035 a share · Warrants at US$3.91 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: General corporate purposes, including pre-clinical and clinical development of product candidates, working capital and capital expenditures | Jan 8, 2025 |